Rythmol (propafenone) dosing, indications, interactions, adverse effects, and more (original) (raw)

All Interactions Sort By:

Contraindicated (6)

• dofetilide
  propafenone, dofetilide. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Additive cardiac effects.
• fezolinetant
  propafenone will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitors
• mavorixafor
  mavorixafor will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Mavorixafor (a strong CYP2D6 inhibitor) is contraindicated with drugs that are highly dependent on CYP2D6 for clearance.
• nirmatrelvir
  nirmatrelvir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.
• nirmatrelvir/ritonavir
  nirmatrelvir/ritonavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.
• tipranavir
  tipranavir increases levels of propafenone by decreasing metabolism. Contraindicated.

Serious (88)

• adagrasib
  adagrasib, propafenone. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
• afatinib
  propafenone increases levels of afatinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Reduce afatinib daily dose by 10 mg if not tolerated when coadministered with P-gp inhibitors.
• alfuzosin
  alfuzosin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• amisulpride
  amisulpride and propafenone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
• anagrelide
  anagrelide and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• apomorphine
  apomorphine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• aripiprazole
  aripiprazole and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• artemether
  artemether and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• artemether/lumefantrine
  artemether/lumefantrine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
• asenapine
  asenapine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• asenapine transdermal
  asenapine transdermal and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• atomoxetine
  atomoxetine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• bosutinib
  propafenone increases levels of bosutinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.
• buprenorphine
  buprenorphine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• buprenorphine buccal
  buprenorphine buccal and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• buprenorphine subdermal implant
  buprenorphine subdermal implant and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• buprenorphine transdermal
  buprenorphine transdermal and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• buprenorphine, long-acting injection
  buprenorphine, long-acting injection and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• ceritinib
  ceritinib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• chlorpromazine
  propafenone will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
• clarithromycin
  clarithromycin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• clozapine
  clozapine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• dacomitinib
  dacomitinib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities.
• dasatinib
  dasatinib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• degarelix
  degarelix and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• desflurane
  desflurane and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• digoxin
  propafenone increases levels of digoxin by decreasing renal clearance. Avoid or Use Alternate Drug.
• diltiazem
  diltiazem will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of diltiazem with pimozide may increase the serum concentration of pimozide (eg, ventricular tachycardia, torsade de pointes, cardiac arrest, sudden death).
• dolasetron
  dolasetron and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• donepezil
  donepezil and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• dronedarone
  dronedarone will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Prolongation of the QT interval with possible development of cardiac arrhythmias possible with co-administration. Concurrent use of drugs that prolong the QTc interval is contraindicated with dronedarone.
• edoxaban
  propafenone will increase the level or effect of edoxaban by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Dose adjustment may be required with strong P-gp inhibitors. DVT/PE treatment: Decrease dose to 30 mg PO once daily. NVAF: No dose reduction recommended
• efavirenz
  efavirenz and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• eliglustat
  eliglustat and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• encorafenib
  encorafenib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• entrectinib
  propafenone and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.
• eribulin
  eribulin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• fexinidazole
  fexinidazole and propafenone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.
• fingolimod
  fingolimod and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• fluoxetine
  fluoxetine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.propafenone will increase the level or effect of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.propafenone and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug.
• gemifloxacin
  gemifloxacin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• gilteritinib
  gilteritinib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• givinostat
  propafenone and givinostat both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold if QTc interval >500 ms or a change from baseline >60 ms.
• givosiran
  givosiran will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.
• glasdegib
  propafenone and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
• granisetron
  granisetron and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• hydroxychloroquine sulfate
  hydroxychloroquine sulfate and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• hydroxyzine
  hydroxyzine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• inotuzumab
  inotuzumab and propafenone both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.
• isoflurane
  isoflurane and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• itraconazole
  itraconazole and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• ivosidenib
  ivosidenib and propafenone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
• lefamulin
  lefamulin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• lithium
  lithium and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• lumefantrine
  lumefantrine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
• macimorelin
  macimorelin and propafenone both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
• mirtazapine
  mirtazapine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• nilotinib
  nilotinib will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Additive QT prolongation may occur during coadministration of nilotinib and propafenone. Coadministration of nilotinib and a drug that prolongs the QT interval is not advised
• olanzapine
  olanzapine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• ondansetron
  propafenone and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
• oxaliplatin
  oxaliplatin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• panobinostat
  propafenone and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
• paroxetine
  paroxetine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.propafenone will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Monitor heart rate and EKG in patients receiving concurrent paroxetine and propafenone. Doses may need to be reduced.
• pimozide
  propafenone, pimozide. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of prolonged QTc interval.
• pitolisant
  propafenone and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.
• pomalidomide
  propafenone increases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.
• ponesimod
  ponesimod, propafenone. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients.
• primaquine
  primaquine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• quinidine
  quinidine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
• repotrectinib
  propafenone will increase the level or effect of repotrectinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.
• ribociclib
  ribociclib will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.ribociclib increases toxicity of propafenone by QTc interval. Avoid or Use Alternate Drug.
• rimegepant
  propafenone will increase the level or effect of rimegepant by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.
• riociguat
  propafenone will increase the level or effect of riociguat by decreasing metabolism. Avoid or Use Alternate Drug. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed
• risperidone
  propafenone will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of propafenone and risperidone is not recommended due to the potential for inducing life-threatening arrhythmias. If concurrent use cannot be avoided, cautious dosing and telemetric monitoring is advised.
• ritonavir
  ritonavir will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Concurrent use of propafenone and ritonavir is contraindicated.ritonavir increases levels of propafenone by decreasing metabolism. Contraindicated.
• siponimod
  siponimod and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• solifenacin
  solifenacin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• sunitinib
  sunitinib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• tacrolimus
  tacrolimus and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• tetrabenazine
  tetrabenazine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
• thioridazine
  propafenone will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of thioridazine and agents that prolong the QT interval, such as Class I antiarrhythmic agents, is contraindicated.thioridazine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of thioridazine and agents that prolong the QT interval, such as Class I antiarrhythmic agents, is contraindicated.
• toremifene
  propafenone and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
• umeclidinium bromide/vilanterol inhaled
  propafenone increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
• vandetanib
  propafenone, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
• vemurafenib
  vemurafenib and propafenone both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.
• venetoclax
  propafenone will increase the level or effect of venetoclax by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If a P-gp inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities.
• vilanterol/fluticasone furoate inhaled
  propafenone increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
• vorinostat
  vorinostat and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

Monitor Closely (151)

• abiraterone
  abiraterone increases levels of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.
• albuterol
  albuterol and propafenone both increase QTc interval. Use Caution/Monitor.
• alfuzosin
  propafenone and alfuzosin both increase QTc interval. Use Caution/Monitor.
• amiodarone
  amiodarone will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Generally avoid combination because of increased risk of QTc interval.
• amobarbital
  amobarbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.
• antithrombin alfa
  propafenone increases effects of antithrombin alfa by decreasing metabolism. Use Caution/Monitor.
• antithrombin III
  propafenone increases effects of antithrombin III by decreasing metabolism. Use Caution/Monitor.
• arformoterol
  arformoterol and propafenone both increase QTc interval. Use Caution/Monitor.
• argatroban
  propafenone increases effects of argatroban by decreasing metabolism. Use Caution/Monitor.
• asenapine
  asenapine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• atomoxetine
  propafenone will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• azithromycin
  azithromycin increases toxicity of propafenone by QTc interval. Use Caution/Monitor.
• bedaquiline
  propafenone and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
• bemiparin
  propafenone increases effects of bemiparin by decreasing metabolism. Use Caution/Monitor.
• benzgalantamine
  benzgalantamine, propafenone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Galantamine, an acetylcholinesterase inhibitor, has vagotonic effects on the SA and AV nodes, leading to bradycardia. Consider consulting a cardiolist before initiating other drugs that may cause bradycardia.
• benzhydrocodone/acetaminophen
  propafenone will increase the level or effect of benzhydrocodone/acetaminophen by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone [benzhydrocodone is prodrug of hydrocodone]) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone.
• berotralstat
  propafenone increases levels of berotralstat by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
• betrixaban
  propafenone increases levels of betrixaban by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Decrease betrixaban dose to 80 mg PO once, then 40 mg PO qDay if coadministered with a P-gp inhibitor.
• bivalirudin
  propafenone increases effects of bivalirudin by decreasing metabolism. Use Caution/Monitor.
• bupropion
  bupropion will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• butabarbital
  butabarbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.
• butalbital
  butalbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.
• carbamazepine
  carbamazepine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• carvedilol
  propafenone will increase the level or effect of carvedilol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• celecoxib
  celecoxib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• ceritinib
  propafenone increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
• chloroquine
  chloroquine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.chloroquine increases toxicity of propafenone by QTc interval. Use Caution/Monitor.
• cimetidine
  cimetidine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.cimetidine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• citalopram
  propafenone and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
• clarithromycin
  clarithromycin will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• clobazam
  clobazam will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly.
• clomipramine
  propafenone will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• cobicistat
  cobicistat will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics.
• crizotinib
  crizotinib and propafenone both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
• dabigatran
  propafenone will increase the level or effect of dabigatran by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Atrial fibrillation: Avoid coadministering dabigatran with P-gp inhibitors if CrCl <30 mL/min. DVT/PE treatment: Avoid coadministering dabigatran with P-gp inhibitors if CrCl <50 mL/min
• dalteparin
  propafenone increases effects of dalteparin by decreasing metabolism. Use Caution/Monitor.
• darifenacin
  darifenacin will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• darunavir
  darunavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics.
• deferasirox
  deferasirox will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• desipramine
  propafenone will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• desvenlafaxine
  desvenlafaxine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
• deutetrabenazine
  deutetrabenazine and propafenone both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
• dichlorphenamide
  dichlorphenamide and propafenone both decrease serum potassium. Use Caution/Monitor.
• diphenhydramine
  diphenhydramine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• dofetilide
  dofetilide increases toxicity of propafenone by QTc interval. Use Caution/Monitor.
• doxepin
  propafenone will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.doxepin and propafenone both increase QTc interval. Use Caution/Monitor.
• dronedarone
  dronedarone will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• duloxetine
  duloxetine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.propafenone will increase the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• duvelisib
  propafenone will increase the level or effect of duvelisib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
• eliglustat
  eliglustat increases levels of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.
• enoxaparin
  propafenone increases effects of enoxaparin by decreasing metabolism. Use Caution/Monitor.
• erythromycin base
  erythromycin base will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• erythromycin ethylsuccinate
  erythromycin ethylsuccinate will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• erythromycin lactobionate
  erythromycin lactobionate will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• erythromycin stearate
  erythromycin stearate will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• escitalopram
  escitalopram increases toxicity of propafenone by QTc interval. Use Caution/Monitor.
• ezogabine
  ezogabine, propafenone. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
• fedratinib
  fedratinib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.
• flecainide
  propafenone will increase the level or effect of flecainide by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• fluphenazine
  propafenone will increase the level or effect of fluphenazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• fluvoxamine
  fluvoxamine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• fondaparinux
  propafenone increases effects of fondaparinux by decreasing metabolism. Use Caution/Monitor.
• fostemsavir
  propafenone and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
• gadobenate
  gadobenate and propafenone both increase QTc interval. Use Caution/Monitor.
• galantamine
  galantamine, propafenone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Galantamine, an acetylcholinesterase inhibitor, has vagotonic effects on the SA and AV nodes, leading to bradycardia. Consider consulting a cardiolist before initiating other drugs that may cause bradycardia.
• gemtuzumab
  propafenone and gemtuzumab both increase QTc interval. Use Caution/Monitor.
• glecaprevir/pibrentasvir
  propafenone will increase the level or effect of glecaprevir/pibrentasvir by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
• goserelin
  goserelin increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
• grapefruit
  grapefruit increases levels of propafenone by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
• haloperidol
  haloperidol will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. If concurrent use cannot be avoided, cautious dosing and telemetric monitoring is advised.haloperidol and propafenone both increase QTc interval. Use Caution/Monitor.
• hawthorn
  hawthorn increases effects of propafenone by pharmacodynamic synergism. Use Caution/Monitor.
• heparin
  propafenone increases effects of heparin by decreasing metabolism. Use Caution/Monitor.
• histrelin
  histrelin increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
• hydrocodone
  propafenone will increase the level or effect of hydrocodone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone.
• hydromorphone
  propafenone will increase the level or effect of hydromorphone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• iloperidone
  propafenone will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• imatinib
  imatinib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• imipramine
  propafenone will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• indacaterol, inhaled
  indacaterol, inhaled, propafenone. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
• isoniazid
  isoniazid will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• itraconazole
  itraconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Closely monitor for evidence of propafenone toxicity when used together with a strong CYP3A4 inhibitor. Avoid concurrent use of a CYP2D6 inhibitor in patients receiving proprafenone and a CYP3A4 inhibitor.
• ketoconazole
  ketoconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• lenvatinib
  propafenone and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
• letermovir
  letermovir increases levels of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• leuprolide
  leuprolide increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
• levoketoconazole
  levoketoconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• lofepramine
  propafenone will increase the level or effect of lofepramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• lorcaserin
  lorcaserin will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• maraviroc
  maraviroc will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• marijuana
  marijuana will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• mavorixafor
  mavorixafor and propafenone both increase QTc interval. Modify Therapy/Monitor Closely. Mavorixafor causes concentration-dependent QTc prolongation. Monitor QTc during treatment in patients with risk factors for QTc prolongation (eg, coadministered medications that increase mavorixafor exposure or other drugs with a high risk to prolong the QTc interval). Mavorixafor dose reduction or discontinuation may be required. propafenone will increase the level or effect of mavorixafor by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor mavorixafor if coadministered with P-gp inhibitors and reduce mavorixafor dose if needed.
• methamphetamine
  propafenone will increase the level or effect of methamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• metoprolol
  propafenone will increase the level or effect of metoprolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. If concurrent therapy is required, monitor cardiac function carefully, particularly blood pressure. A dosage adjustment for the beta blocker may be required.
• mexiletine
  propafenone will increase the level or effect of mexiletine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• mifepristone
  mifepristone, propafenone. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.
• mirabegron
  mirabegron will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• morphine
  propafenone will increase the level or effect of morphine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• naldemedine
  propafenone increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor naldemedine for potential adverse effects if coadministered with P-gp inhibitors.
• nebivolol
  propafenone will increase the level or effect of nebivolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Reduced doses of nebivolol may be necessary.
• nefazodone
  nefazodone will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• nilotinib
  nilotinib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• nintedanib
  propafenone increases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy .
• nortriptyline
  propafenone will increase the level or effect of nortriptyline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• olodaterol inhaled
  propafenone and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
• ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)
  ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when coadministered with Viekira Pak
• osimertinib
  osimertinib and propafenone both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
• oxaliplatin
  oxaliplatin will increase the level or effect of propafenone by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
• oxycodone
  propafenone will increase the level or effect of oxycodone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• oxymorphone
  propafenone will increase the level or effect of oxymorphone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• ozanimod
  ozanimod and propafenone both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
• parecoxib
  parecoxib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• pasireotide
  propafenone and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
• peginterferon alfa 2b
  peginterferon alfa 2b, propafenone. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.
• pentobarbital
  pentobarbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.
• perphenazine
  perphenazine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.propafenone will increase the level or effect of perphenazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• phenindione
  propafenone increases effects of phenindione by decreasing metabolism. Use Caution/Monitor.
• phenobarbital
  phenobarbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.
• primidone
  primidone decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.
• prochlorperazine
  propafenone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• promazine
  propafenone will increase the level or effect of promazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• promethazine
  propafenone will increase the level or effect of promethazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• propranolol
  propafenone will increase the level or effect of propranolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. If concurrent therapy is required, monitor cardiac function carefully, particularly blood pressure. A dosage adjustment for the beta blocker may be required.
• protamine
  propafenone increases effects of protamine by decreasing metabolism. Use Caution/Monitor.
• quetiapine
  quetiapine, propafenone. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
• quinacrine
  quinacrine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• quinine
  propafenone and quinine both increase QTc interval. Use Caution/Monitor.
• quizartinib
  quizartinib, propafenone. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.
• ranolazine
  ranolazine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• rifabutin
  rifabutin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• rifampin
  rifampin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rifampin decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.
• rifaximin
  propafenone increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
• rilpivirine
  rilpivirine increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes.
• rolapitant
  rolapitant will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration.
• selpercatinib
  selpercatinib increases toxicity of propafenone by QTc interval. Use Caution/Monitor.
• sevelamer
  sevelamer decreases levels of propafenone by increasing elimination. Use Caution/Monitor.
• sevoflurane
  sevoflurane and propafenone both increase QTc interval. Use Caution/Monitor.
• sorafenib
  sorafenib and propafenone both increase QTc interval. Use Caution/Monitor.
• St John's Wort
  St John's Wort will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
• talazoparib
  propafenone will increase the level or effect of talazoparib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Talazoparib is a P-glycoprotein (P-gp) substrate; coadministration with P-gp inhibitors may increase talazoparib systemic exposure.
• tamoxifen
  propafenone decreases effects of tamoxifen by decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.
• terbinafine
  terbinafine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.
• timolol
  propafenone will increase the level or effect of timolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• tipranavir
  tipranavir will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• tolterodine
  propafenone will increase the level or effect of tolterodine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Use caution when prescribing propafenone concurrently with tolterodine. Concomitant use of propafenone and tolterodine may cause QT prolongation.
• tramadol
  propafenone decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Decreased conversion of tramadol to active metabolite.propafenone decreases effects of tramadol by decreasing metabolism. Use Caution/Monitor. Decreased conversion of tramadol to active metabolite.
• triclabendazole
  triclabendazole and propafenone both increase QTc interval. Use Caution/Monitor.
• trifluoperazine
  propafenone will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• triptorelin
  triptorelin increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
• valbenazine
  valbenazine and propafenone both increase QTc interval. Use Caution/Monitor.
• venlafaxine
  venlafaxine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
• viloxazine
  viloxazine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Viloxazine (a weak CYP2D6 inhibitor) may increase systemic exposure of CYP2D6 substrates. Monitor and adjust dose of substrate as clinically indicated.

Minor (69)

• amobarbital
  amobarbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• amphetamine
  propafenone will increase the level or effect of amphetamine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• aprepitant
  aprepitant will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• aripiprazole
  propafenone will increase the level or effect of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• armodafinil
  armodafinil will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• artemether/lumefantrine
  artemether/lumefantrine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• atazanavir
  atazanavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• bosentan
  bosentan will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• budesonide
  budesonide will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• butabarbital
  butabarbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• butalbital
  butalbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• codeine
  propafenone will increase the level or effect of codeine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.propafenone decreases effects of codeine by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of codeine to active metabolite morphine.

• conivaptan
  conivaptan will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• cortisone
  cortisone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• cyclosporine
  cyclosporine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• darifenacin
  darifenacin will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• dasatinib
  dasatinib will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• dexamethasone
  dexamethasone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• dexfenfluramine
  propafenone will increase the level or effect of dexfenfluramine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• dextroamphetamine
  propafenone will increase the level or effect of dextroamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• dextromethorphan
  propafenone will increase the level or effect of dextromethorphan by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• DHEA, herbal
  DHEA, herbal will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• donepezil
  propafenone will increase the level or effect of donepezil by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• efavirenz
  efavirenz will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• encainide
  propafenone will increase the level or effect of encainide by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• eslicarbazepine acetate
  eslicarbazepine acetate will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• etravirine
  etravirine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• fesoterodine
  propafenone will increase the level or effect of fesoterodine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• fluconazole
  fluconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• fludrocortisone
  fludrocortisone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• food
  food increases levels of propafenone by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

• fosamprenavir
  fosamprenavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• fosaprepitant
  fosaprepitant will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• fosphenytoin
  fosphenytoin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• grapefruit
  grapefruit will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• griseofulvin
  griseofulvin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• hydrocortisone
  hydrocortisone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• lapatinib
  lapatinib will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• lily of the valley
  propafenone, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

• loratadine
  propafenone will increase the level or effect of loratadine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• lumefantrine
  lumefantrine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• marijuana
  marijuana will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• methylprednisolone
  methylprednisolone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• metronidazole
  metronidazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• miconazole vaginal
  miconazole vaginal will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• nelfinavir
  nelfinavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• nevirapine
  nevirapine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• nifedipine
  nifedipine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• oxcarbazepine
  oxcarbazepine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• oxycodone
  propafenone decreases effects of oxycodone by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of oxycodone to active metabolite morphine.

• pentobarbital
  pentobarbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• perhexiline
  propafenone will increase the level or effect of perhexiline by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• phenobarbital
  phenobarbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• phenytoin
  phenytoin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• posaconazole
  posaconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• prednisone
  prednisone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• primidone
  primidone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• quinupristin/dalfopristin
  quinupristin/dalfopristin will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• rifabutin
  rifabutin decreases levels of propafenone by increasing metabolism. Minor/Significance Unknown.

• rifapentine
  rifapentine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• ritonavir
  ritonavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• rufinamide
  rufinamide will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• sertraline
  sertraline will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown. Monitor the EKG in patients receiving concurrent propafenone and sertraline. Doses of propafenone may need to be reduced.

• theophylline
  propafenone increases levels of theophylline by decreasing renal clearance. Minor/Significance Unknown.

• topiramate
  topiramate will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• tropisetron
  propafenone will increase the level or effect of tropisetron by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• verapamil
  verapamil will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• voriconazole
  voriconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• zafirlukast
  zafirlukast will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• abiraterone
  Monitor Closely (1)abiraterone increases levels of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.

• adagrasib
  Serious - Use Alternative (1)adagrasib, propafenone. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.

• afatinib
  Serious - Use Alternative (1)propafenone increases levels of afatinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Reduce afatinib daily dose by 10 mg if not tolerated when coadministered with P-gp inhibitors.

• albuterol
  Monitor Closely (1)albuterol and propafenone both increase QTc interval. Use Caution/Monitor.

• alfuzosin
  Monitor Closely (1)propafenone and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• amiodarone
  Monitor Closely (1)amiodarone will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Generally avoid combination because of increased risk of QTc interval.

• amisulpride
  Serious - Use Alternative (1)amisulpride and propafenone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

• amobarbital
  Monitor Closely (1)amobarbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.Minor (1)amobarbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• amphetamine
  Minor (1)propafenone will increase the level or effect of amphetamine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• anagrelide
  Serious - Use Alternative (1)anagrelide and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• antithrombin alfa
  Monitor Closely (1)propafenone increases effects of antithrombin alfa by decreasing metabolism. Use Caution/Monitor.

• antithrombin III
  Monitor Closely (1)propafenone increases effects of antithrombin III by decreasing metabolism. Use Caution/Monitor.

• apomorphine
  Serious - Use Alternative (1)apomorphine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• aprepitant
  Minor (1)aprepitant will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• arformoterol
  Monitor Closely (1)arformoterol and propafenone both increase QTc interval. Use Caution/Monitor.

• argatroban
  Monitor Closely (1)propafenone increases effects of argatroban by decreasing metabolism. Use Caution/Monitor.

• aripiprazole
  Serious - Use Alternative (1)aripiprazole and propafenone both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)propafenone will increase the level or effect of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• armodafinil
  Minor (1)armodafinil will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• artemether
  Serious - Use Alternative (1)artemether and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• artemether/lumefantrine
  Serious - Use Alternative (1)artemether/lumefantrine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.Minor (1)artemether/lumefantrine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• asenapine
  Monitor Closely (1)asenapine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)asenapine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• asenapine transdermal
  Serious - Use Alternative (1)asenapine transdermal and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• atazanavir
  Minor (1)atazanavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• atomoxetine
  Monitor Closely (1)propafenone will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)atomoxetine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• azithromycin
  Monitor Closely (1)azithromycin increases toxicity of propafenone by QTc interval. Use Caution/Monitor.

• bedaquiline
  Monitor Closely (1)propafenone and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely

• bemiparin
  Monitor Closely (1)propafenone increases effects of bemiparin by decreasing metabolism. Use Caution/Monitor.

• benzgalantamine
  Monitor Closely (1)benzgalantamine, propafenone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Galantamine, an acetylcholinesterase inhibitor, has vagotonic effects on the SA and AV nodes, leading to bradycardia. Consider consulting a cardiolist before initiating other drugs that may cause bradycardia.

• benzhydrocodone/acetaminophen
  Monitor Closely (1)propafenone will increase the level or effect of benzhydrocodone/acetaminophen by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone [benzhydrocodone is prodrug of hydrocodone]) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone.

• berotralstat
  Monitor Closely (1)propafenone increases levels of berotralstat by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

• betrixaban
  Monitor Closely (1)propafenone increases levels of betrixaban by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Decrease betrixaban dose to 80 mg PO once, then 40 mg PO qDay if coadministered with a P-gp inhibitor.

• bivalirudin
  Monitor Closely (1)propafenone increases effects of bivalirudin by decreasing metabolism. Use Caution/Monitor.

• bosentan
  Minor (1)bosentan will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• bosutinib
  Serious - Use Alternative (1)propafenone increases levels of bosutinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.

• budesonide
  Minor (1)budesonide will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• buprenorphine
  Serious - Use Alternative (1)buprenorphine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine buccal
  Serious - Use Alternative (1)buprenorphine buccal and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine subdermal implant
  Serious - Use Alternative (1)buprenorphine subdermal implant and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine transdermal
  Serious - Use Alternative (1)buprenorphine transdermal and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine, long-acting injection
  Serious - Use Alternative (1)buprenorphine, long-acting injection and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• bupropion
  Monitor Closely (1)bupropion will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• butabarbital
  Monitor Closely (1)butabarbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.Minor (1)butabarbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• butalbital
  Monitor Closely (1)butalbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.Minor (1)butalbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• carbamazepine
  Monitor Closely (1)carbamazepine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• carvedilol
  Monitor Closely (1)propafenone will increase the level or effect of carvedilol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• celecoxib
  Monitor Closely (1)celecoxib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• ceritinib
  Monitor Closely (1)propafenone increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.Serious - Use Alternative (1)ceritinib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• chloroquine
  Monitor Closely (2)chloroquine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
  chloroquine increases toxicity of propafenone by QTc interval. Use Caution/Monitor.

• chlorpromazine
  Serious - Use Alternative (1)propafenone will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.

• cimetidine
  Monitor Closely (2)cimetidine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
  cimetidine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• citalopram
  Monitor Closely (1)propafenone and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

• clarithromycin
  Monitor Closely (1)clarithromycin will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)clarithromycin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• clobazam
  Monitor Closely (1)clobazam will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly.

• clomipramine
  Monitor Closely (1)propafenone will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• clozapine
  Serious - Use Alternative (1)clozapine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• cobicistat
  Monitor Closely (1)cobicistat will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics.

• codeine
  Minor (2)propafenone will increase the level or effect of codeine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.
  propafenone decreases effects of codeine by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of codeine to active metabolite morphine.

• conivaptan
  Minor (1)conivaptan will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• cortisone
  Minor (1)cortisone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• crizotinib
  Monitor Closely (1)crizotinib and propafenone both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

• cyclosporine
  Minor (1)cyclosporine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• dabigatran
  Monitor Closely (1)propafenone will increase the level or effect of dabigatran by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Atrial fibrillation: Avoid coadministering dabigatran with P-gp inhibitors if CrCl <30 mL/min. DVT/PE treatment: Avoid coadministering dabigatran with P-gp inhibitors if CrCl <50 mL/min

• dacomitinib
  Serious - Use Alternative (1)dacomitinib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities.

• dalteparin
  Monitor Closely (1)propafenone increases effects of dalteparin by decreasing metabolism. Use Caution/Monitor.

• darifenacin
  Monitor Closely (1)darifenacin will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Minor (1)darifenacin will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• darunavir
  Monitor Closely (1)darunavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics.

• dasatinib
  Serious - Use Alternative (1)dasatinib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)dasatinib will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• deferasirox
  Monitor Closely (1)deferasirox will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• degarelix
  Serious - Use Alternative (1)degarelix and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• desflurane
  Serious - Use Alternative (1)desflurane and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• desipramine
  Monitor Closely (1)propafenone will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• desvenlafaxine
  Monitor Closely (1)desvenlafaxine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg

• deutetrabenazine
  Monitor Closely (1)deutetrabenazine and propafenone both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).

• dexamethasone
  Minor (1)dexamethasone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• dexfenfluramine
  Minor (1)propafenone will increase the level or effect of dexfenfluramine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• dextroamphetamine
  Minor (1)propafenone will increase the level or effect of dextroamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• dextromethorphan
  Minor (1)propafenone will increase the level or effect of dextromethorphan by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• DHEA, herbal
  Minor (1)DHEA, herbal will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• dichlorphenamide
  Monitor Closely (1)dichlorphenamide and propafenone both decrease serum potassium. Use Caution/Monitor.

• digoxin
  Serious - Use Alternative (1)propafenone increases levels of digoxin by decreasing renal clearance. Avoid or Use Alternate Drug.

• diltiazem
  Serious - Use Alternative (1)diltiazem will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of diltiazem with pimozide may increase the serum concentration of pimozide (eg, ventricular tachycardia, torsade de pointes, cardiac arrest, sudden death).

• diphenhydramine
  Monitor Closely (1)diphenhydramine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• dofetilide
  Contraindicated (1)propafenone, dofetilide. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Additive cardiac effects.Monitor Closely (1)dofetilide increases toxicity of propafenone by QTc interval. Use Caution/Monitor.

• dolasetron
  Serious - Use Alternative (1)dolasetron and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• donepezil
  Serious - Use Alternative (1)donepezil and propafenone both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)propafenone will increase the level or effect of donepezil by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• doxepin
  Monitor Closely (2)propafenone will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
  doxepin and propafenone both increase QTc interval. Use Caution/Monitor.

• dronedarone
  Monitor Closely (1)dronedarone will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)dronedarone will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Prolongation of the QT interval with possible development of cardiac arrhythmias possible with co-administration. Concurrent use of drugs that prolong the QTc interval is contraindicated with dronedarone.

• duloxetine
  Monitor Closely (2)duloxetine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
  propafenone will increase the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• duvelisib
  Monitor Closely (1)propafenone will increase the level or effect of duvelisib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

• edoxaban
  Serious - Use Alternative (1)propafenone will increase the level or effect of edoxaban by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Dose adjustment may be required with strong P-gp inhibitors. DVT/PE treatment: Decrease dose to 30 mg PO once daily. NVAF: No dose reduction recommended

• efavirenz
  Serious - Use Alternative (1)efavirenz and propafenone both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)efavirenz will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• eliglustat
  Monitor Closely (1)eliglustat increases levels of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.Serious - Use Alternative (1)eliglustat and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• encainide
  Minor (1)propafenone will increase the level or effect of encainide by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• encorafenib
  Serious - Use Alternative (1)encorafenib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• enoxaparin
  Monitor Closely (1)propafenone increases effects of enoxaparin by decreasing metabolism. Use Caution/Monitor.

• entrectinib
  Serious - Use Alternative (1)propafenone and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.

• eribulin
  Serious - Use Alternative (1)eribulin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• erythromycin base
  Monitor Closely (1)erythromycin base will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• erythromycin ethylsuccinate
  Monitor Closely (1)erythromycin ethylsuccinate will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• erythromycin lactobionate
  Monitor Closely (1)erythromycin lactobionate will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• erythromycin stearate
  Monitor Closely (1)erythromycin stearate will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• escitalopram
  Monitor Closely (1)escitalopram increases toxicity of propafenone by QTc interval. Use Caution/Monitor.

• eslicarbazepine acetate
  Minor (1)eslicarbazepine acetate will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• etravirine
  Minor (1)etravirine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• ezogabine
  Monitor Closely (1)ezogabine, propafenone. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.

• fedratinib
  Monitor Closely (1)fedratinib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.

• fesoterodine
  Minor (1)propafenone will increase the level or effect of fesoterodine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• fexinidazole
  Serious - Use Alternative (1)fexinidazole and propafenone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.

• fezolinetant
  Contraindicated (1)propafenone will increase the level or effect of fezolinetant by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Fezolinetant AUC and peak plasma concentration are increased if coadministered with drugs that are weak, moderate, or strong CYP1A2 inhibitors

• fingolimod
  Serious - Use Alternative (1)fingolimod and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• flecainide
  Monitor Closely (1)propafenone will increase the level or effect of flecainide by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• fluconazole
  Minor (1)fluconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• fludrocortisone
  Minor (1)fludrocortisone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• fluoxetine
  Serious - Use Alternative (3)propafenone and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug.
  fluoxetine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
  propafenone will increase the level or effect of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.

• fluphenazine
  Monitor Closely (1)propafenone will increase the level or effect of fluphenazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• fluvoxamine
  Monitor Closely (1)fluvoxamine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• fondaparinux
  Monitor Closely (1)propafenone increases effects of fondaparinux by decreasing metabolism. Use Caution/Monitor.

• food
  Minor (1)food increases levels of propafenone by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

• fosamprenavir
  Minor (1)fosamprenavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• fosaprepitant
  Minor (1)fosaprepitant will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• fosphenytoin
  Minor (1)fosphenytoin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• fostemsavir
  Monitor Closely (1)propafenone and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.

• gadobenate
  Monitor Closely (1)gadobenate and propafenone both increase QTc interval. Use Caution/Monitor.

• galantamine
  Monitor Closely (1)galantamine, propafenone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Galantamine, an acetylcholinesterase inhibitor, has vagotonic effects on the SA and AV nodes, leading to bradycardia. Consider consulting a cardiolist before initiating other drugs that may cause bradycardia.

• gemifloxacin
  Serious - Use Alternative (1)gemifloxacin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• gemtuzumab
  Monitor Closely (1)propafenone and gemtuzumab both increase QTc interval. Use Caution/Monitor.

• gilteritinib
  Serious - Use Alternative (1)gilteritinib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• givinostat
  Serious - Use Alternative (1)propafenone and givinostat both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold if QTc interval >500 ms or a change from baseline >60 ms.

• givosiran
  Serious - Use Alternative (1)givosiran will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.

• glasdegib
  Serious - Use Alternative (1)propafenone and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.

• glecaprevir/pibrentasvir
  Monitor Closely (1)propafenone will increase the level or effect of glecaprevir/pibrentasvir by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

• goserelin
  Monitor Closely (1)goserelin increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

• granisetron
  Serious - Use Alternative (1)granisetron and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• grapefruit
  Monitor Closely (1)grapefruit increases levels of propafenone by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.Minor (1)grapefruit will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• griseofulvin
  Minor (1)griseofulvin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• haloperidol
  Monitor Closely (2)haloperidol will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. If concurrent use cannot be avoided, cautious dosing and telemetric monitoring is advised.
  haloperidol and propafenone both increase QTc interval. Use Caution/Monitor.

• hawthorn
  Monitor Closely (1)hawthorn increases effects of propafenone by pharmacodynamic synergism. Use Caution/Monitor.

• heparin
  Monitor Closely (1)propafenone increases effects of heparin by decreasing metabolism. Use Caution/Monitor.

• histrelin
  Monitor Closely (1)histrelin increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

• hydrocodone
  Monitor Closely (1)propafenone will increase the level or effect of hydrocodone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Hydromorphone (<3% of the circulating parent hydrocodone) is mainly formed by CYP2D6 mediated O-demethylation of hydrocodone. Hydromorphone may contribute to the total analgesic effect of hydrocodone.

• hydrocortisone
  Minor (1)hydrocortisone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• hydromorphone
  Monitor Closely (1)propafenone will increase the level or effect of hydromorphone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• hydroxychloroquine sulfate
  Serious - Use Alternative (1)hydroxychloroquine sulfate and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• hydroxyzine
  Serious - Use Alternative (1)hydroxyzine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• iloperidone
  Monitor Closely (1)propafenone will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• imatinib
  Monitor Closely (1)imatinib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• imipramine
  Monitor Closely (1)propafenone will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• indacaterol, inhaled
  Monitor Closely (1)indacaterol, inhaled, propafenone. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.

• inotuzumab
  Serious - Use Alternative (1)inotuzumab and propafenone both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.

• isoflurane
  Serious - Use Alternative (1)isoflurane and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• isoniazid
  Monitor Closely (1)isoniazid will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• itraconazole
  Monitor Closely (1)itraconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Closely monitor for evidence of propafenone toxicity when used together with a strong CYP3A4 inhibitor. Avoid concurrent use of a CYP2D6 inhibitor in patients receiving proprafenone and a CYP3A4 inhibitor.Serious - Use Alternative (1)itraconazole and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• ivosidenib
  Serious - Use Alternative (1)ivosidenib and propafenone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.

• ketoconazole
  Monitor Closely (1)ketoconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• lapatinib
  Minor (1)lapatinib will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• lefamulin
  Serious - Use Alternative (1)lefamulin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• lenvatinib
  Monitor Closely (1)propafenone and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.

• letermovir
  Monitor Closely (1)letermovir increases levels of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• leuprolide
  Monitor Closely (1)leuprolide increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

• levoketoconazole
  Monitor Closely (1)levoketoconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• lily of the valley
  Minor (1)propafenone, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

• lithium
  Serious - Use Alternative (1)lithium and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• lofepramine
  Monitor Closely (1)propafenone will increase the level or effect of lofepramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• loratadine
  Minor (1)propafenone will increase the level or effect of loratadine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• lorcaserin
  Monitor Closely (1)lorcaserin will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• lumefantrine
  Serious - Use Alternative (1)lumefantrine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.Minor (1)lumefantrine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• macimorelin
  Serious - Use Alternative (1)macimorelin and propafenone both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.

• maraviroc
  Monitor Closely (1)maraviroc will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• marijuana
  Monitor Closely (1)marijuana will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Minor (1)marijuana will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• mavorixafor
  Contraindicated (1)mavorixafor will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. Mavorixafor (a strong CYP2D6 inhibitor) is contraindicated with drugs that are highly dependent on CYP2D6 for clearance.Monitor Closely (2)mavorixafor and propafenone both increase QTc interval. Modify Therapy/Monitor Closely. Mavorixafor causes concentration-dependent QTc prolongation. Monitor QTc during treatment in patients with risk factors for QTc prolongation (eg, coadministered medications that increase mavorixafor exposure or other drugs with a high risk to prolong the QTc interval). Mavorixafor dose reduction or discontinuation may be required.
  propafenone will increase the level or effect of mavorixafor by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor mavorixafor if coadministered with P-gp inhibitors and reduce mavorixafor dose if needed.

• methamphetamine
  Monitor Closely (1)propafenone will increase the level or effect of methamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• methylprednisolone
  Minor (1)methylprednisolone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• metoprolol
  Monitor Closely (1)propafenone will increase the level or effect of metoprolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. If concurrent therapy is required, monitor cardiac function carefully, particularly blood pressure. A dosage adjustment for the beta blocker may be required.

• metronidazole
  Minor (1)metronidazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• mexiletine
  Monitor Closely (1)propafenone will increase the level or effect of mexiletine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• miconazole vaginal
  Minor (1)miconazole vaginal will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• mifepristone
  Monitor Closely (1)mifepristone, propafenone. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.

• mirabegron
  Monitor Closely (1)mirabegron will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• mirtazapine
  Serious - Use Alternative (1)mirtazapine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• morphine
  Monitor Closely (1)propafenone will increase the level or effect of morphine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• naldemedine
  Monitor Closely (1)propafenone increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor naldemedine for potential adverse effects if coadministered with P-gp inhibitors.

• nebivolol
  Monitor Closely (1)propafenone will increase the level or effect of nebivolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Reduced doses of nebivolol may be necessary.

• nefazodone
  Monitor Closely (1)nefazodone will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• nelfinavir
  Minor (1)nelfinavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• nevirapine
  Minor (1)nevirapine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• nifedipine
  Minor (1)nifedipine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• nilotinib
  Monitor Closely (1)nilotinib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)nilotinib will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Additive QT prolongation may occur during coadministration of nilotinib and propafenone. Coadministration of nilotinib and a drug that prolongs the QT interval is not advised

• nintedanib
  Monitor Closely (1)propafenone increases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy .

• nirmatrelvir
  Contraindicated (1)nirmatrelvir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.

• nirmatrelvir/ritonavir
  Contraindicated (1)nirmatrelvir/ritonavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.

• nortriptyline
  Monitor Closely (1)propafenone will increase the level or effect of nortriptyline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• olanzapine
  Serious - Use Alternative (1)olanzapine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• olodaterol inhaled
  Monitor Closely (1)propafenone and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias

• ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)
  Monitor Closely (1)ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when coadministered with Viekira Pak

• ondansetron
  Serious - Use Alternative (1)propafenone and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.

• osimertinib
  Monitor Closely (1)osimertinib and propafenone both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.

• oxaliplatin
  Monitor Closely (1)oxaliplatin will increase the level or effect of propafenone by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.Serious - Use Alternative (1)oxaliplatin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• oxcarbazepine
  Minor (1)oxcarbazepine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• oxycodone
  Monitor Closely (1)propafenone will increase the level or effect of oxycodone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Minor (1)propafenone decreases effects of oxycodone by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of oxycodone to active metabolite morphine.

• oxymorphone
  Monitor Closely (1)propafenone will increase the level or effect of oxymorphone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• ozanimod
  Monitor Closely (1)ozanimod and propafenone both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.

• panobinostat
  Serious - Use Alternative (1)propafenone and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.

• parecoxib
  Monitor Closely (1)parecoxib will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• paroxetine
  Serious - Use Alternative (2)paroxetine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
  propafenone will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Monitor heart rate and EKG in patients receiving concurrent paroxetine and propafenone. Doses may need to be reduced.

• pasireotide
  Monitor Closely (1)propafenone and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.

• peginterferon alfa 2b
  Monitor Closely (1)peginterferon alfa 2b, propafenone. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.

• pentobarbital
  Monitor Closely (1)pentobarbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.Minor (1)pentobarbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• perhexiline
  Minor (1)propafenone will increase the level or effect of perhexiline by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• perphenazine
  Monitor Closely (2)perphenazine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
  propafenone will increase the level or effect of perphenazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• phenindione
  Monitor Closely (1)propafenone increases effects of phenindione by decreasing metabolism. Use Caution/Monitor.

• phenobarbital
  Monitor Closely (1)phenobarbital decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.Minor (1)phenobarbital will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• phenytoin
  Minor (1)phenytoin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• pimozide
  Serious - Use Alternative (1)propafenone, pimozide. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of prolonged QTc interval.

• pitolisant
  Serious - Use Alternative (1)propafenone and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.

• pomalidomide
  Serious - Use Alternative (1)propafenone increases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.

• ponesimod
  Serious - Use Alternative (1)ponesimod, propafenone. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients.

• posaconazole
  Minor (1)posaconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• prednisone
  Minor (1)prednisone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• primaquine
  Serious - Use Alternative (1)primaquine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• primidone
  Monitor Closely (1)primidone decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.Minor (1)primidone will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• prochlorperazine
  Monitor Closely (1)propafenone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• promazine
  Monitor Closely (1)propafenone will increase the level or effect of promazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• promethazine
  Monitor Closely (1)propafenone will increase the level or effect of promethazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• propranolol
  Monitor Closely (1)propafenone will increase the level or effect of propranolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. If concurrent therapy is required, monitor cardiac function carefully, particularly blood pressure. A dosage adjustment for the beta blocker may be required.

• protamine
  Monitor Closely (1)propafenone increases effects of protamine by decreasing metabolism. Use Caution/Monitor.

• quetiapine
  Monitor Closely (1)quetiapine, propafenone. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.

• quinacrine
  Monitor Closely (1)quinacrine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• quinidine
  Serious - Use Alternative (1)quinidine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.

• quinine
  Monitor Closely (1)propafenone and quinine both increase QTc interval. Use Caution/Monitor.

• quinupristin/dalfopristin
  Minor (1)quinupristin/dalfopristin will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• quizartinib
  Monitor Closely (1)quizartinib, propafenone. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.

• ranolazine
  Monitor Closely (1)ranolazine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• repotrectinib
  Serious - Use Alternative (1)propafenone will increase the level or effect of repotrectinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.

• ribociclib
  Serious - Use Alternative (2)ribociclib will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
  ribociclib increases toxicity of propafenone by QTc interval. Avoid or Use Alternate Drug.

• rifabutin
  Monitor Closely (1)rifabutin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Minor (1)rifabutin decreases levels of propafenone by increasing metabolism. Minor/Significance Unknown.

• rifampin
  Monitor Closely (2)rifampin decreases levels of propafenone by increasing metabolism. Use Caution/Monitor.
  rifampin will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• rifapentine
  Minor (1)rifapentine will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• rifaximin
  Monitor Closely (1)propafenone increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

• rilpivirine
  Monitor Closely (1)rilpivirine increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes.

• rimegepant
  Serious - Use Alternative (1)propafenone will increase the level or effect of rimegepant by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.

• riociguat
  Serious - Use Alternative (1)propafenone will increase the level or effect of riociguat by decreasing metabolism. Avoid or Use Alternate Drug. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed

• risperidone
  Serious - Use Alternative (1)propafenone will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of propafenone and risperidone is not recommended due to the potential for inducing life-threatening arrhythmias. If concurrent use cannot be avoided, cautious dosing and telemetric monitoring is advised.

• ritonavir
  Serious - Use Alternative (2)ritonavir will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Concurrent use of propafenone and ritonavir is contraindicated.
  ritonavir increases levels of propafenone by decreasing metabolism. Contraindicated.Minor (1)ritonavir will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• rolapitant
  Monitor Closely (1)rolapitant will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration.

• rufinamide
  Minor (1)rufinamide will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• selpercatinib
  Monitor Closely (1)selpercatinib increases toxicity of propafenone by QTc interval. Use Caution/Monitor.

• sertraline
  Minor (1)sertraline will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown. Monitor the EKG in patients receiving concurrent propafenone and sertraline. Doses of propafenone may need to be reduced.

• sevelamer
  Monitor Closely (1)sevelamer decreases levels of propafenone by increasing elimination. Use Caution/Monitor.

• sevoflurane
  Monitor Closely (1)sevoflurane and propafenone both increase QTc interval. Use Caution/Monitor.

• siponimod
  Serious - Use Alternative (1)siponimod and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• solifenacin
  Serious - Use Alternative (1)solifenacin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• sorafenib
  Monitor Closely (1)sorafenib and propafenone both increase QTc interval. Use Caution/Monitor.

• St John's Wort
  Monitor Closely (1)St John's Wort will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

• sunitinib
  Serious - Use Alternative (1)sunitinib and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• tacrolimus
  Serious - Use Alternative (1)tacrolimus and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• talazoparib
  Monitor Closely (1)propafenone will increase the level or effect of talazoparib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Talazoparib is a P-glycoprotein (P-gp) substrate; coadministration with P-gp inhibitors may increase talazoparib systemic exposure.

• tamoxifen
  Monitor Closely (1)propafenone decreases effects of tamoxifen by decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.

• terbinafine
  Monitor Closely (1)terbinafine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.

• tetrabenazine
  Serious - Use Alternative (1)tetrabenazine and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• theophylline
  Minor (1)propafenone increases levels of theophylline by decreasing renal clearance. Minor/Significance Unknown.

• thioridazine
  Serious - Use Alternative (2)propafenone will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of thioridazine and agents that prolong the QT interval, such as Class I antiarrhythmic agents, is contraindicated.
  thioridazine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. The concurrent administration of thioridazine and agents that prolong the QT interval, such as Class I antiarrhythmic agents, is contraindicated.

• timolol
  Monitor Closely (1)propafenone will increase the level or effect of timolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• tipranavir
  Contraindicated (1)tipranavir increases levels of propafenone by decreasing metabolism. Contraindicated.Monitor Closely (1)tipranavir will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• tolterodine
  Monitor Closely (1)propafenone will increase the level or effect of tolterodine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Use caution when prescribing propafenone concurrently with tolterodine. Concomitant use of propafenone and tolterodine may cause QT prolongation.

• topiramate
  Minor (1)topiramate will decrease the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• toremifene
  Serious - Use Alternative (1)propafenone and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.

• tramadol
  Monitor Closely (2)propafenone decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Decreased conversion of tramadol to active metabolite.
  propafenone decreases effects of tramadol by decreasing metabolism. Use Caution/Monitor. Decreased conversion of tramadol to active metabolite.

• triclabendazole
  Monitor Closely (1)triclabendazole and propafenone both increase QTc interval. Use Caution/Monitor.

• trifluoperazine
  Monitor Closely (1)propafenone will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• triptorelin
  Monitor Closely (1)triptorelin increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

• tropisetron
  Minor (1)propafenone will increase the level or effect of tropisetron by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.

• umeclidinium bromide/vilanterol inhaled
  Serious - Use Alternative (1)propafenone increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

• valbenazine
  Monitor Closely (1)valbenazine and propafenone both increase QTc interval. Use Caution/Monitor.

• vandetanib
  Serious - Use Alternative (1)propafenone, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.

• vemurafenib
  Serious - Use Alternative (1)vemurafenib and propafenone both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.

• venetoclax
  Serious - Use Alternative (1)propafenone will increase the level or effect of venetoclax by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If a P-gp inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities.

• venlafaxine
  Monitor Closely (1)venlafaxine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.

• verapamil
  Minor (1)verapamil will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• vilanterol/fluticasone furoate inhaled
  Serious - Use Alternative (1)propafenone increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

• viloxazine
  Monitor Closely (1)viloxazine will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Viloxazine (a weak CYP2D6 inhibitor) may increase systemic exposure of CYP2D6 substrates. Monitor and adjust dose of substrate as clinically indicated.

• voriconazole
  Minor (1)voriconazole will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

• vorinostat
  Serious - Use Alternative (1)vorinostat and propafenone both increase QTc interval. Avoid or Use Alternate Drug.

• zafirlukast
  Minor (1)zafirlukast will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.